CTLA4 and pneumonitis: Furthermore, the incidence of pneumonitis is higher when PD-1/PD-L1 inhibitors are used in combination with CTLA-4 inhibitors or sequential with chemotherapy, radiotherapy, or other immunotherapies than when used as a monotherapy [24,128,129,144,145,146,147,148].